Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Patients with recurrent or refractory solid tumors or brain tumors that are unresponsive to
conventional therapy, or with no known effective therapy, will be treated. Experiments in the
laboratory have shown the experimental drug RAD001C (RAD001, Everolimus) can prevent cells
from multiplying. RAD001 is now being tested in diseases such as cancer, in which excessive
cell multiplication needs to be stopped. The drug has been tested in adult cancer patients
and has been well tolerated by subjects in these studies. It is experimental and, therefore,
available in clinical trials.